Verastem, Inc. (VSTM)

NASDAQ: VSTM · IEX Real-Time Price · USD
1.01
+0.56 (125.55%)
May 26, 2023, 4:00 PM EDT - Market closed
125.55%
Market Cap 202.87M
Revenue (ttm) n/a
Net Income (ttm) -72.56M
Shares Out 200.86M
EPS (ttm) -0.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 84,076,159
Open 1.00
Previous Close 0.45
Day's Range 0.46 - 1.21
52-Week Range 0.29 - 1.47
Beta 0.79
Analysts Strong Buy
Price Target 3.00 (+197.03%)
Earnings Date May 9, 2023

About VSTM

Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination wi... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 27, 2012
Employees 57
Stock Exchange NASDAQ
Ticker Symbol VSTM
Full Company Profile

Financial Performance

In 2022, Verastem's revenue was $2.60 million, an increase of 26.45% compared to the previous year's $2.05 million. Losses were -$73.81 million, 3.67% more than in 2021.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for VSTM stock is "Strong Buy." The 12-month stock price forecast is $3.0, which is an increase of 197.03% from the latest price.

Price Target
$3.0
(197.03% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced updated data from Part A of the on...

4 days ago - Business Wire

Verastem Oncology Appoints Karin Tollefson, PhD, to Board of Directors

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Karin Tollefson ...

1 week ago - Business Wire

Verastem Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the first qua...

2 weeks ago - Business Wire

Verastem Oncology to Participate in Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will participate...

1 month ago - Business Wire

New Data from Interim Analysis of Verastem Oncology's RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at the American Society of Clinical Oncology Annual Meeting

BOSTON--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that an abstract highlighting upd...

1 month ago - Business Wire

Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days

BOSTON--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will present at ...

1 month ago - Business Wire

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purch...

1 month ago - Business Wire

New Verastem Oncology Initiative, Let's Talk About LGSOC, Calls Attention to Rare Form of Ovarian Cancer

BOSTON--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the launch of Let's Talk About LG...

2 months ago - Business Wire

Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three mon...

2 months ago - Business Wire

Top 3 stocks under $1 to buy in March

With the third month of 2023 already well underway, the ripple effect from the collapse of multiple banks in the United States is felt far and wide, leaving investors to wonder which stocks are worthy...

Other symbols: CYBNITRG
2 months ago - Finbold

Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today outlined key strategic priorities and u...

4 months ago - Business Wire

Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred Stock

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it has entered into a defini...

4 months ago - Business Wire

Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announces positive interim data from Part ...

4 months ago - Business Wire

Verastem Oncology Appoints Rob Gagnon to Board of Directors

BOSTONBOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Robert G...

5 months ago - Business Wire

Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three mon...

7 months ago - Business Wire

Verastem Oncology Appoints Anil Kapur to Board of Directors

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Anil Kapur to it...

7 months ago - Business Wire

Verastem Oncology Announces RAMP VS-6766 Clinical Trials and Corporate Updates

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced an update on its RAMP (Raf And Mek ...

8 months ago - Business Wire

Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three mon...

10 months ago - Business Wire

RBC Says Verastem Interim Analysis In Ovarian Cancer Reinforces Enthusiasm

With the anticipation of a 2Q program update, Verastem Oncology (NASDAQ: VSTM) announced that its interim analysis findings for the RAMP 201 program for recurrent low-grade serous ovarian cancer (LGSO...

1 year ago - Benzinga

Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 ± Defactinib in Low-Grade Serous Ovarian Cancer

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for people living with cancer, today announced an update from an interim ana...

1 year ago - Business Wire

Verastem Oncology Awarded Pancreatic Cancer Action Network's First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it has received the first “Th...

1 year ago - Business Wire

Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three mon...

1 year ago - Business Wire

Verastem Announces $150M Debt Financing To Support VS-6766, Defactinib Development

Verastem Oncology Inc (NASDAQ: VSTM) entered into a credit facility with Oxford Finance LLC for up to $150 million to primarily support the continued development, commercial preparation, and potential...

1 year ago - Benzinga

Verastem Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three mon...

1 year ago - Business Wire

Verastem Oncology Provides Financial Update to Support Development of VS-6766 and Defactinib in RAS Pathway-Driven Tumors

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced it has entered into a credit facil...

1 year ago - Business Wire